FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386778082> ?p ?o ?g. }

• W4386778082 endingPage "2538" @default.
• W4386778082 startingPage "2538" @default.
• W4386778082 abstract "The first-generation tropomyosin receptor kinase (TRK) inhibitors, larotrectinib and entrectinib, represent exciting new developments in cancer treatment that offer relevant, rapid, and long-lasting clinical benefits. Larotrectinib and entrectinib are recommended as first-line treatments for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with positive TRK gene fusions. In this study, using the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database between 2019 and 2022, a retrospective analysis was conducted to evaluate the safety profiles of these drugs. During our study period, 807 individual case safety reports (ICSRs) related to larotrectinib or entrectinib were retrieved from the FAERS database, of which 48.7% referred to females and 24.7% referred to adult patients (18–64 years) with a median age of 61.0 years. A total of 1728 adverse drug reactions (ADRs) were identified. The most frequently reported ADRs were dizziness and pain, which belong to the System Organ Classes (SOCs) “nervous system disorders” and “general disorders and administration site conditions”. Regarding all ADRs, the median time to onset was 37.0 days for larotrectinib and 12.0 days for entrectinib. No evident safety concerns emerged in the long-term safety profiles (>365 days). Only 18 ICSRs were related to pediatric populations (≤16 years), of which 94.0% of the ICSRs were related to larotrectinib. The median age was 10.5 years, while most patients were female (44.4%). Our results show favorable risk-benefit profiles for larotrectinib and entrectinib. Considering the increased use of neurotrophic tyrosine receptor kinase (NTRK) inhibitors, continuous safety monitoring of larotrectinib and entrectinib is required for the detection of possible new adverse drug reactions." @default.
• W4386778082 created "2023-09-16" @default.
• W4386778082 creator A5016680176 @default.
• W4386778082 creator A5032246167 @default.
• W4386778082 creator A5040328648 @default.
• W4386778082 creator A5040919526 @default.
• W4386778082 creator A5058915028 @default.
• W4386778082 creator A5063767788 @default.
• W4386778082 creator A5085334357 @default.
• W4386778082 date "2023-09-15" @default.
• W4386778082 modified "2023-10-17" @default.
• W4386778082 title "The Safety Profiles of Two First-Generation NTRK Inhibitors: Analysis of Individual Case Safety Reports from the FDA Adverse Event Reporting System (FAERS) Database" @default.
• W4386778082 cites W2017331060 @default.
• W4386778082 cites W2028370869 @default.
• W4386778082 cites W2065990496 @default.
• W4386778082 cites W2090909991 @default.
• W4386778082 cites W2110647409 @default.
• W4386778082 cites W2113514677 @default.
• W4386778082 cites W2201685611 @default.
• W4386778082 cites W2618891896 @default.
• W4386778082 cites W2725207489 @default.
• W4386778082 cites W2763584377 @default.
• W4386778082 cites W2795040138 @default.
• W4386778082 cites W2884163715 @default.
• W4386778082 cites W2996574710 @default.
• W4386778082 cites W3007610090 @default.
• W4386778082 cites W3016832416 @default.
• W4386778082 cites W3026620415 @default.
• W4386778082 cites W3033773215 @default.
• W4386778082 cites W3047189699 @default.
• W4386778082 cites W3090991802 @default.
• W4386778082 cites W3114345108 @default.
• W4386778082 cites W3130131060 @default.
• W4386778082 cites W3132427319 @default.
• W4386778082 cites W3135209648 @default.
• W4386778082 cites W3158162879 @default.
• W4386778082 cites W3168226229 @default.
• W4386778082 cites W3215197047 @default.
• W4386778082 cites W4200353020 @default.
• W4386778082 cites W4213448131 @default.
• W4386778082 cites W4225966443 @default.
• W4386778082 cites W4293558780 @default.
• W4386778082 cites W4309067313 @default.
• W4386778082 cites W4309089758 @default.
• W4386778082 doi "https://doi.org/10.3390/biomedicines11092538" @default.
• W4386778082 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37760979" @default.
• W4386778082 hasPublicationYear "2023" @default.
• W4386778082 type Work @default.
• W4386778082 citedByCount "0" @default.
• W4386778082 crossrefType "journal-article" @default.
• W4386778082 hasAuthorship W4386778082A5016680176 @default.
• W4386778082 hasAuthorship W4386778082A5032246167 @default.
• W4386778082 hasAuthorship W4386778082A5040328648 @default.
• W4386778082 hasAuthorship W4386778082A5040919526 @default.
• W4386778082 hasAuthorship W4386778082A5058915028 @default.
• W4386778082 hasAuthorship W4386778082A5063767788 @default.
• W4386778082 hasAuthorship W4386778082A5085334357 @default.
• W4386778082 hasBestOaLocation W43867780821 @default.
• W4386778082 hasConcept C121608353 @default.
• W4386778082 hasConcept C126322002 @default.
• W4386778082 hasConcept C134139212 @default.
• W4386778082 hasConcept C143998085 @default.
• W4386778082 hasConcept C170493617 @default.
• W4386778082 hasConcept C197934379 @default.
• W4386778082 hasConcept C2777105317 @default.
• W4386778082 hasConcept C3018359032 @default.
• W4386778082 hasConcept C3018890749 @default.
• W4386778082 hasConcept C41008148 @default.
• W4386778082 hasConcept C71924100 @default.
• W4386778082 hasConcept C77088390 @default.
• W4386778082 hasConcept C92020748 @default.
• W4386778082 hasConcept C98274493 @default.
• W4386778082 hasConceptScore W4386778082C121608353 @default.
• W4386778082 hasConceptScore W4386778082C126322002 @default.
• W4386778082 hasConceptScore W4386778082C134139212 @default.
• W4386778082 hasConceptScore W4386778082C143998085 @default.
• W4386778082 hasConceptScore W4386778082C170493617 @default.
• W4386778082 hasConceptScore W4386778082C197934379 @default.
• W4386778082 hasConceptScore W4386778082C2777105317 @default.
• W4386778082 hasConceptScore W4386778082C3018359032 @default.
• W4386778082 hasConceptScore W4386778082C3018890749 @default.
• W4386778082 hasConceptScore W4386778082C41008148 @default.
• W4386778082 hasConceptScore W4386778082C71924100 @default.
• W4386778082 hasConceptScore W4386778082C77088390 @default.
• W4386778082 hasConceptScore W4386778082C92020748 @default.
• W4386778082 hasConceptScore W4386778082C98274493 @default.
• W4386778082 hasIssue "9" @default.
• W4386778082 hasLocation W43867780821 @default.
• W4386778082 hasLocation W43867780822 @default.
• W4386778082 hasOpenAccess W4386778082 @default.
• W4386778082 hasPrimaryLocation W43867780821 @default.
• W4386778082 hasRelatedWork W1926424129 @default.
• W4386778082 hasRelatedWork W2117787550 @default.
• W4386778082 hasRelatedWork W2138694088 @default.
• W4386778082 hasRelatedWork W2331674283 @default.
• W4386778082 hasRelatedWork W2332079099 @default.
• W4386778082 hasRelatedWork W2909892243 @default.
• W4386778082 hasRelatedWork W2978916037 @default.

• next